GB201213712D0 - Modified therapeutic agents - Google Patents

Modified therapeutic agents

Info

Publication number: GB201213712D0
Authority: GB; United Kingdom
Prior art keywords: therapeutic agents; modified therapeutic; modified; agents; therapeutic
Prior art date: 2012-08-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1213712.1A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LEVERTON LICENCE HOLDINGS Ltd

Original Assignee

LEVERTON LICENCE HOLDINGS Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-01

Filing date

2012-08-01

Publication date

2012-09-12

2012-08-01 Application filed by LEVERTON LICENCE HOLDINGS Ltd filed Critical LEVERTON LICENCE HOLDINGS Ltd

2012-08-01 Priority to GBGB1213712.1A priority Critical patent/GB201213712D0/en

2012-09-12 Publication of GB201213712D0 publication Critical patent/GB201213712D0/en

2013-04-16 Priority to EP13719043.5A priority patent/EP2838566A2/en

2013-04-16 Priority to CN201380027958.3A priority patent/CN104411335A/en

2013-04-16 Priority to PE2014001639A priority patent/PE20150226A1/en

2013-04-16 Priority to JP2015504987A priority patent/JP2015512927A/en

2013-04-16 Priority to IN8598DEN2014 priority patent/IN2014DN08598A/en

2013-04-16 Priority to HK15100881.5A priority patent/HK1200695A1/en

2013-04-16 Priority to PCT/EP2013/057928 priority patent/WO2013156488A2/en

2013-04-16 Priority to MYPI2014002900A priority patent/MY190257A/en

2013-04-16 Priority to GBGB1910190.6A priority patent/GB201910190D0/en

2013-04-16 Priority to CA2869993A priority patent/CA2869993C/en

2013-04-16 Priority to GEAP201313632A priority patent/GEP201706716B/en

2013-04-16 Priority to MX2014012512A priority patent/MX2014012512A/en

2013-04-16 Priority to AP2014008049A priority patent/AP2014008049A0/en

2013-04-16 Priority to GB1418864.3A priority patent/GB2516388A/en

2013-04-16 Priority to IL235129A priority patent/IL235129B/en

2013-04-16 Priority to MD20140123A priority patent/MD20140123A2/en

2013-04-16 Priority to AU2013248296A priority patent/AU2013248296A1/en

2013-04-16 Priority to US14/394,437 priority patent/US20150086524A1/en

2013-04-16 Priority to GBGB1910184.9A priority patent/GB201910184D0/en

2013-04-16 Priority to KR1020147031042A priority patent/KR102137290B1/en

2013-04-16 Priority to SG11201406492YA priority patent/SG11201406492YA/en

2013-04-16 Priority to NZ701205A priority patent/NZ701205A/en

2013-04-16 Priority to EA201491702A priority patent/EA033469B1/en

2013-04-16 Priority to BR112014025737A priority patent/BR112014025737A2/en

2014-10-10 Priority to ZA2014/07370A priority patent/ZA201407370B/en

2014-10-14 Priority to CR20140475A priority patent/CR20140475A/en

2014-10-15 Priority to PH12014502314A priority patent/PH12014502314B1/en

2014-10-15 Priority to NI201400122A priority patent/NI201400122A/en

2014-10-15 Priority to CL2014002773A priority patent/CL2014002773A1/en

2014-10-16 Priority to ECIEPI201423048A priority patent/ECSP14023048A/en

2014-10-16 Priority to MX2020014208A priority patent/MX2020014208A/en

2014-11-14 Priority to CO14252826A priority patent/CO7151496A2/en

2017-08-30 Priority to US15/691,090 priority patent/US11351112B2/en

2017-09-06 Priority to JP2017171545A priority patent/JP6550107B2/en

2018-01-05 Priority to AU2018200111A priority patent/AU2018200111B2/en

2019-04-05 Priority to JP2019073048A priority patent/JP2019131593A/en

2020-02-06 Priority to AU2020200842A priority patent/AU2020200842A1/en

Status Ceased legal-status Critical Current

Priority Applications (38)

Application Number	Priority Date	Filing Date	Title
GBGB1213712.1A GB201213712D0 (en)	2012-08-01	2012-08-01	Modified therapeutic agents
BR112014025737A BR112014025737A2 (en)	2012-04-16	2013-04-16	method for administering a therapeutic agent, method for preventing entry of a therapeutic agent, method for modulating the rate of release of a therapeutic agent, therapeutic agent, dosage forms, method of treating a disease and parts kit
US14/394,437 US20150086524A1 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
GBGB1910184.9A GB201910184D0 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
PE2014001639A PE20150226A1 (en)	2012-04-16	2013-04-16	OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
JP2015504987A JP2015512927A (en)	2012-04-16	2013-04-16	Optimized subcutaneous therapy
IN8598DEN2014 IN2014DN08598A (en)	2012-04-16	2013-04-16
HK15100881.5A HK1200695A1 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
MYPI2014002900A MY190257A (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
GBGB1910190.6A GB201910190D0 (en)	2012-04-16	2013-04-16	Optimised subsutaneous therapeutic agents
SG11201406492YA SG11201406492YA (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
GEAP201313632A GEP201706716B (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
MX2014012512A MX2014012512A (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents.
AP2014008049A AP2014008049A0 (en)	2012-04-16	2013-04-16	Optimised subcuraneous therapeutic agents
GB1418864.3A GB2516388A (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
IL235129A IL235129B (en)	2012-04-16	2013-04-16	Therapeutic compounds for subcutaneous administration
MD20140123A MD20140123A2 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
AU2013248296A AU2013248296A1 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
EP13719043.5A EP2838566A2 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
KR1020147031042A KR102137290B1 (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
CN201380027958.3A CN104411335A (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
CA2869993A CA2869993C (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
NZ701205A NZ701205A (en)	2012-04-16	2013-04-16	Optimised subcutaneous therapeutic agents
EA201491702A EA033469B1 (en)	2012-04-16	2013-04-16	Subcutaneous administration of blood factor conjugates with polyethylene glycol
ZA2014/07370A ZA201407370B (en)	2012-04-16	2014-10-10	Optimised subcutaneous therapeutic agents
CR20140475A CR20140475A (en)	2012-04-16	2014-10-14	OPTIMIZED SUBCUTANEOUS ADMINISTRATION THERAPEUTIC AGENTS
PH12014502314A PH12014502314B1 (en)	2012-04-16	2014-10-15	Optimised subcutaneous therapeutic agents
NI201400122A NI201400122A (en)	2012-04-16	2014-10-15	THERAPEUTIC AGENTS FOR OPTIMIZED SUBCUTANEOUS ADMINISTRATION
CL2014002773A CL2014002773A1 (en)	2012-04-16	2014-10-15	A subcutaneous dosage form of a pharmaceutical composition of a blood coagulation factor selected from factor vii, viia, viii, ix, x, xa, xi, xiii, v, von willebrand factor and protein c, conjugated with a polyethylene glycol molecule (peg), where the dosage of the factor is 100 and 250 iu / kg or 25 and 50 iu / kg, and where the peg molecule is conjugated directly or indirectly.
MX2020014208A MX2020014208A (en)	2012-04-16	2014-10-16	Optimised subcutaneous therapeutic agents.
ECIEPI201423048A ECSP14023048A (en)	2012-04-16	2014-10-16	OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
CO14252826A CO7151496A2 (en)	2012-04-16	2014-11-14	Therapeutic agents for optimized subcutaneous administration
US15/691,090 US11351112B2 (en)	2012-04-16	2017-08-30	Optimised subcutaneous therapeutic agents
JP2017171545A JP6550107B2 (en)	2012-04-16	2017-09-06	Optimized subcutaneous drug
AU2018200111A AU2018200111B2 (en)	2012-04-16	2018-01-05	Optimised subcutaneous therapeutic agents
JP2019073048A JP2019131593A (en)	2012-04-16	2019-04-05	Optimized subcutaneous therapeutic agents
AU2020200842A AU2020200842A1 (en)	2012-04-16	2020-02-06	Optimised subcutaneous therapeutic agents

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1213712.1A GB201213712D0 (en)	2012-08-01	2012-08-01	Modified therapeutic agents

Publications (1)

Publication Number	Publication Date
GB201213712D0 true GB201213712D0 (en)	2012-09-12

Family

ID=46881521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1213712.1A Ceased GB201213712D0 (en)	2012-04-16	2012-08-01	Modified therapeutic agents

Country Status (1)

Country	Link
GB (1)	GB201213712D0 (en)

2012
- 2012-08-01 GB GBGB1213712.1A patent/GB201213712D0/en not_active Ceased

Publication	Publication Date	Title
GB201212513D0 (en)	2012-08-29	Therapeutic agents
IL233756A0 (en)	2014-09-30	Novel therapeutic agents
ZA201305897B (en)	2014-04-30	Combination therapy
GB201321729D0 (en)	2014-01-22	Therapeutic agents
GB201321728D0 (en)	2014-01-22	Therapeutic agents
GB201321730D0 (en)	2014-01-22	Therapeutic agents
GB201114212D0 (en)	2011-10-05	Therapeutic agents
ZA201400120B (en)	2015-09-30	Combination therapy
EP2867209A4 (en)	2015-11-25	Compounds and therapeutic uses thereof
GB201119401D0 (en)	2011-12-21	Therapeutic agents
GB201321737D0 (en)	2014-01-22	Therapeutic Agents
GB201217439D0 (en)	2012-11-14	Combination therapy
GB201910190D0 (en)	2019-08-28	Optimised subsutaneous therapeutic agents
GB201321745D0 (en)	2014-01-22	Therapeutic agents
GB201321731D0 (en)	2014-01-22	Therapeutic agents
GB201217704D0 (en)	2012-11-14	Therapeutic agents
GB201207305D0 (en)	2012-06-13	Therapy
EP2701744A4 (en)	2014-08-20	Combination therapy
GB201420971D0 (en)	2015-01-07	Therapeutic composition
EP2879707A4 (en)	2016-05-11	Combination therapy
IL217807A0 (en)	2012-06-28	Therapeutic compositions
EP2804853A4 (en)	2015-09-23	Therapeutic uses
GB201215184D0 (en)	2012-10-10	Therapeutic virus
GB201214985D0 (en)	2012-10-03	Modified therapeutic agents
GB201213712D0 (en)	2012-09-12	Modified therapeutic agents

Legal Events

Date	Code	Title	Description
2014-01-29	AT	Applications terminated before publication under section 16(1)
2017-07-26	S30Z	Assignments for licence or security reasons	Free format text: APPLICANT. LEVERTON LICENCE HOLDINGS LIMITED SECURITY INTEREST. FONDS RUSNANO CAPITAL S.A.